Fused pyrazine derivatives as A2A / A2B inhibitors

US11999740B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Xiaozhao Wang · Readington, US
• Peter Carlsen · Claymont, US
• Pei Gan · Claymont, US
• Gia Hoang · Wilmington, US
• Yong Li · Newark, US
• Chao Qi · Newark, US
• Liangxing Wu · Wilmington, US
• Wenqing Yao · Kennett Square, US
• Wenyu Zhu · Wilmington, US

Key dates

• Filing date: Oct 13, 2021
• Grant date: Jun 4, 2024
• Expiry date: Oct 13, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.